Modelling paper using data from prospective clinical trials highlights major impact of higher doses of primaquine and tafenoquine on P.vivax recurrences and #vivax transmission. Coverage, adherence and safety will be key elements in implementation.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00689-3/fulltext
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00689-3/fulltext
Comments